Metabolic differences affecting energy production were observed in endothelial cells — the cells that line blood vessels — from patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). These distinctions could underlie differences in disease mechanisms and necessary treatment approaches, according to a recent study.
A generic molecule that works by activating a mitochrondrial protein, dichloroacetate (DCA), was seen in a Phase 1 clinical trial to reduce pulmonary arterial blood pressure and improve lung function in patients with pulmonary arterial hypertension (PAH). In PAH, cells of blood vessels adopt characteristics that are similar to cancer cells,…
A compound that scientists have been examining as a cancer therapy reduced blood pressure in pulmonary hypertension patients’ lungs, according to a clinical trial. Researchers tested the therapy, dichloroacetic acid, in 20 patients with pulmonary arterial hypertension, or PAH. Although all responded, some with particular gene mutations failed to respond as well,…
The cost to treat pulmonary arterial hypertension (PAH) is often exceedingly high, costing more than $200,000 annually. Rare disease markets are much smaller than the typical drug market, meaning the cost of treatments for rare diseases, such as PAH, are priced higher than treatments…
Get regular updates to your inbox.